Thalidomide with or without Dexamethasone for Refractory or Relapsing Multiple Myeloma

Seminars in Hematology

Volumn 40, Issue 4 SUPPL. 4, 2003, Pages 3-7

  Alexanian, Raymond ^a   Weber, Donna ^a   Anagnostopoulos, Athanasios ^a   Delasalle, Kay ^a   Wang, Michael ^a   Rankin, Kim ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; PARAPROTEIN; THALIDOMIDE; VINCRISTINE;

ADULT; ANKLE EDEMA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRADYCARDIA; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG MIXTURE; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; HUMAN; ILEUS; INDIGESTION; LUNG EMBOLISM; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OPTIMAL DRUG DOSE; PARESTHESIA; PRIORITY JOURNAL; RASH; TREATMENT WITHDRAWAL; TREMOR; VERTIGO;

EID: 0347383742     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2003.09.006     Document Type: Article

References (17)

1. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
2. Alexanian R, Weber D: Thalidomide for resistant and relapsing myeloma. Semin Hematol 37:22-25, 2000 (suppl)
3. Rajkumar SV, Fonseca R, Dispenzieri A, et al: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75:897-901, 2000
4. Juliusson G, Celsing F, Turesson I, et al: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109:89-96, 2000
5. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86:404-408, 2001
6. Weber DM, Rankin K, Gavino M, et al: Thalidomide with dexamethasone for resistant multiple myeloma. Blood 96:167a, 2000 (abstr)
7. Palumbo A, Giaccone L, Bertola A, et al: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403, 2001
8. Dimopoulos MA, Zervas K, Kouvatseas G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991-995, 2001
9. Weber DM: Thalidomide and its derivatives: New promise for multiple myeloma. Cancer Control (in press)
10. Hideshima T, Chauhan D, Yoshito Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
11. Anagnostopoulos A, Weber D, Rankin K, et al: Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-777, 2003
12. Alexanian R, Weber D, Giralt S, et al: Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27:1037-1043, 2001
13. Alexanian R, Weber D, Giralt S, et al: Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 13:1116-1119, 2002
14. Weber DM, Rankin K, Delasalle K, et al: Thalidomide alone and in combination for previously untreated myeloma. VIIIth International Myeloma Workshop, Banff, Canada, May 4-8, 2001, p 109 (abstr)
15. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002
16. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
17. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003